cyclophosphamide + doxorubicin + fluorouracil + goserelin + methotrexate + tamoxifen

This is a multi-agent combination chemotherapy and endocrine therapy regimen composed of six drugs: - Cyclophosphamide (an alkylating agent) - Doxorubicin (an anthracycline antibiotic) - Fluorouracil (also known as 5-fluorouracil, an antimetabolite/pyrimidine analog) - Goserelin (a gonadotropin-releasing hormone agonist) - Methotrexate (an antimetabolite/antifolate agent) - Tamoxifen (a selective estrogen receptor modulator) Each component has a distinct mechanism of action targeting cancer cell proliferation or hormonal signaling. This combination would be expected to provide both cytotoxic and hormonal blockade effects, primarily for hormone-sensitive cancers such as breast cancer. While combinations of several of these agents are standard in breast cancer treatment regimens, the use of all six together is not a widely established protocol but may be considered in research or highly individualized settings[5][6][10].